An editorial suggests “it may not yet be time to abandon HDL as a target in atherosclerosis research. However, it probably is time to abandon our assumption that fibrates, niacin, or CETP inhibitors will improve clinical outcomes in contemporary populations taking statins simply because they have favourable effects on surrogate lipoprotein biomarkers.”